Your browser is no longer supported. Please, upgrade your browser.
Settings
ITOS [NASD]
iTeos Therapeutics, Inc.
Index- P/E- EPS (ttm)-1.44 Insider Own0.40% Shs Outstand35.09M Perf Week1.06%
Market Cap871.80M Forward P/E- EPS next Y-2.22 Insider Trans-51.22% Shs Float34.85M Perf Month-4.75%
Income-50.40M PEG- EPS next Q-0.41 Inst Own87.80% Short Float2.68% Perf Quarter5.15%
Sales- P/S- EPS this Y-55.40% Inst Trans0.43% Short Ratio1.92 Perf Half Y-23.39%
Book/sh8.91 P/B2.77 EPS next Y-23.30% ROA-17.20% Target Price- Perf Year25.46%
Cash/sh9.10 P/C2.71 EPS next 5Y- ROE-21.80% 52W Range17.43 - 47.61 Perf YTD-27.00%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-48.18% Beta-
Dividend %- Quick Ratio27.50 Sales past 5Y- Gross Margin- 52W Low41.54% ATR1.14
Employees68 Current Ratio27.50 Sales Q/Q- Oper. Margin- RSI (14)51.32 Volatility4.75% 4.56%
OptionableNo Debt/Eq0.00 EPS Q/Q-96.20% Profit Margin- Rel Volume0.40 Prev Close24.69
ShortableYes LT Debt/Eq0.00 EarningsMay 13 AMC Payout- Avg Volume487.42K Price24.67
Recom1.60 SMA20-0.20% SMA505.01% SMA200-13.70% Volume79,616 Change-0.08%
May-05-21Initiated H.C. Wainwright Buy $37
Oct-08-20Initiated Robert W. Baird Outperform $45
Aug-18-20Initiated Wedbush Outperform $45
Aug-18-20Initiated SVB Leerink Outperform $45
Aug-18-20Initiated Piper Sandler Overweight $50
Aug-18-20Initiated JP Morgan Overweight $40
Aug-03-21 07:00AM  
Jul-08-21 10:03AM  
Jun-17-21 06:40AM  
Jun-16-21 02:34PM  
Jun-15-21 08:11AM  
Jun-14-21 04:55PM  
08:42AM  
07:53AM  
07:24AM  
07:18AM  
07:00AM  
06:46AM  
Jun-04-21 09:00AM  
May-26-21 07:00AM  
May-13-21 04:01PM  
02:30PM  
May-06-21 04:01PM  
May-03-21 04:01PM  
Apr-26-21 04:30AM  
Apr-10-21 08:30AM  
Mar-24-21 04:45PM  
Feb-23-21 07:00AM  
Feb-17-21 07:00AM  
Jan-25-21 02:13AM  
Jan-05-21 07:00AM  
Dec-11-20 02:00PM  
Nov-23-20 04:01PM  
Nov-12-20 07:01AM  
07:00AM  
Nov-05-20 04:05PM  
Oct-26-20 08:27AM  
Oct-01-20 10:03AM  
Sep-08-20 04:05PM  
Sep-01-20 05:26PM  
Aug-07-20 08:15PM  
Jul-23-20 10:31PM  
Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients. The company's product pipeline includes inupadenant, a small molecule antagonist of the adenosine A2a receptor that is an open-label Phase 1/2a clinical trial in adult patients; and EOS-448, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1/2a clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity. Iteos Therapeutics, Inc. was founded in 2011 and is headquartered in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Gall MatthewChief Financial OfficerJun 16Buy26.095,000130,4475,000Jun 16 06:46 PM
Detheux MichelChief Executive OfficerJun 14Sale28.5029,000826,534148,937Jun 16 06:48 PM
McGrath YvonneVP, Research and DevelopmentJun 08Option Exercise4.237,92733,5317,927Jun 10 05:35 PM
McGrath YvonneVP, Research and DevelopmentJun 08Sale20.007,927158,5400Jun 10 05:35 PM
McGrath YvonneVP, Research and DevelopmentJun 02Option Exercise4.233231,366323Jun 03 04:17 PM
McGrath YvonneVP, Research and DevelopmentJun 02Sale20.003236,4600Jun 03 04:17 PM
McGrath YvonneVP, Research and DevelopmentJun 01Option Exercise4.237,60432,1657,604Jun 03 04:17 PM
McGrath YvonneVP, Research and DevelopmentJun 01Sale20.187,604153,4430Jun 03 04:17 PM
McGrath YvonneVP, Research and DevelopmentMay 24Option Exercise4.237,92733,5317,927May 26 04:09 PM
McGrath YvonneVP, Research and DevelopmentMay 24Sale21.927,927173,7960May 26 04:09 PM
McGrath YvonneVP, Research and DevelopmentMay 17Option Exercise4.237,92633,5277,926May 19 04:14 PM
McGrath YvonneVP, Research and DevelopmentMay 17Sale24.697,926195,7190May 19 04:14 PM
MPM BioVentures 2014, L.P.10% OwnerApr 09Sale29.991193,5693,665,787Apr 13 04:16 PM
MPM BIOVENTURES 2018, L.P.10% OwnerApr 09Sale29.991193,5693,665,787Apr 13 04:15 PM
GADICKE ANSBERT10% OwnerApr 09Sale29.992005,9986,004,368Apr 13 04:15 PM
MPM BIOVENTURES 2018, L.P.10% OwnerApr 08Sale30.5219,304589,0893,655,906Apr 09 04:09 PM
MPM BioVentures 2014, L.P.10% OwnerApr 08Sale30.5219,304589,0893,655,906Apr 09 04:10 PM
GADICKE ANSBERT10% OwnerApr 08Sale30.5232,304985,8026,004,568Apr 09 04:47 PM
GADICKE ANSBERT10% OwnerApr 07Sale32.559,678315,0486,052,542Apr 09 04:47 PM
MPM BioVentures 2014, L.P.10% OwnerApr 07Sale32.555,783188,2543,700,880Apr 09 04:10 PM
MPM BIOVENTURES 2018, L.P.10% OwnerApr 07Sale32.555,783188,2543,700,880Apr 09 04:09 PM